APTBIO Secures Hundreds of Millions in Series B Funding to Advance Data-Driven Precision Medicine

VCBeat has learned that, recently,APTBIO, a company focused on the application of mass spectrometry-based multi-omics in precision medicine, has completed a Series B financing round amounting to hundreds of millions of RMB. The round was led by Legend Capital, with Joy Capital serving as the exclusive financial advisor. This funding will support APTBIO’s continued deepening of its expertise in mass spectrometry-based multi-omics applications and in analytical services for innovative drug development and preclinical research. It will also accelerate product development, team building, and market expansion, while enabling forward-looking strategic layout for precision medicine services driven by both big data and AI.

APTBIO was founded in July 2004 as a high-tech enterprise invested and established by the former Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences. As one of the earliest biotechnology companies in China to provide proteomics technical services and biopharmaceutical research and analysis services, it has participated in the entire process of establishing mass spectrometry applications in China from scratch. Headquartered in Shanghai, the company has built innovation technology centers, data centers, and clinical testing centers in Shanghai, Yiwu, and Taizhou, with a total area exceeding 20,000 square meters, and has established a sales network covering the whole country. Focusing on the development of the life and health industry chain, the company has establishedFour Major Technology Platforms: Large-Cohort Multi-Omics Research Platform, Preclinical Pharmaceutical Analysis and Pilot-Scale Production Platform for Biopharmaceuticals, Mass Spectrometry-Based Clinical Testing and Companion Diagnostics Platform, and AI-Driven Big Data Algorithms Platform, LayoutThree Major Business Segments: Technology Services, Biopharmaceutical CRO Services, and Mass Spectrometry-Based Clinical Testing Services, constructing a business landscape centered on multi-omics big data applications for precision discovery, precision diagnosis, and precision therapy.

APTBIO has established comprehensive intelligent laboratories for analytical method development, testing, and production, strictly adhering to CMA, CNAS, and GMP standards. These facilities safeguard the R&D, compliant manufacturing, and integrated registration of biologics and innovative drugs. With 18 years of high-quality service, APTBIO has accumulated extensive experience and a strong reputation, securing its position as a market leader in preclinical CMC (Chemistry, Manufacturing, and Controls). The company has independently built an innovative multi-omics platform centered on proteomics, metabolomics, post-translational modification analysis, transcriptomics, and lipidomics. It has also developed an automated and informatized platform capable of handling ten-thousand-scale cohort samples, providing professional, innovative technologies and product R&D support for advancements in life sciences and clinical translation. Leveraging years of accumulated experience and data, APTBIO possesses the capability to integrate multi-omics and clinical data, offering solutions for precision prevention and personalized treatment. By accelerating the efficient translation of scientific achievements, APTBIO has emerged as an innovative leader in the field of precision medicine.

With the support of this round of financing, the company will continue to deepen its presence in the broader health sector. Upholding the corporate values of “innovation as the foundation, integrity as the priority, and pragmatism as the key,” APTBIO will accelerate the expansion and upgrading of its technology platforms, the development of innovative precision medicine products, the expansion of global marketing channels, and the recruitment of high-end talent. These efforts will strengthen APTBIO’s competitive advantages in mass spectrometry-based multi-omics, positioning it as a data-driven leader in translating multi-omics technologies into clinical applications and innovative drug R&D, thereby advancing the development of China’s precision medicine industry.

Ms. Chen Wei, Founder of APTBIOAPTBIO expressed its gratitude to all investment institutions for their trust in the company. The capital injection in this round fully validates APTBIO’s rapid development and future potential in the fields of mass spectrometry-based multi-omics precision medicine and preclinical CRO services for drug R&D. With the completion of this new round of financing, we will further advance our market layout in both China and globally, accelerate the iteration of innovative biopharmaceutical businesses, and strengthen our data-driven capabilities in precision medicine, thereby contributing value to the global health industry.

Mr. Zhou Hongbin, Co-Chief Investment Officer of Legend CapitalHe expressed his pleasure in collaborating with the management team of APTBIO, as well as its existing shareholders—the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences (CAS), Luxin Venture Capital, and Xi Venture Capital—and extended his gratitude to Legend Capital for their recognition and support. Entrepreneurship among CAS scientific and technical talents has always been a key focus area for Legend Capital, and we highly value investment and cooperation opportunities with companies within the CAS system. As a leading domestic provider of multi-omics R&D services, APTBIO covers multiple fields, including scientific services, biopharmaceutical R&D, and precision medicine, offering integrated solutions to facilitate the translation of basic research into clinical applications. The company has proactively deployed cutting-edge technologies in various fields such as proteomics and metabolomics, with its high-quality R&D team achieving breakthroughs across multiple research areas. We are honored to participate in APTBIO’s future development and look forward to working together to establish the company as an industry leader in multi-omics R&D.

Mr. Ding Yameng, Founding Managing Partner and Chief Operating Officer of Haoyue Capitalstated that the Haoyue team was honored to assist APTBIO in completing its latest round of financing and introducing top-tier long-term partners, thereby laying a solid foundation for the company’s sustained high-speed growth in the future. In recent years, the multi-omics industry has experienced rapid development in the Chinese market, with deep cultivation particularly in genomics, transcriptomics, proteomics, and metabolomics pipelines. APTBIO’s scarcity value is reflected in its platform technology covering all multi-omics pipelines, with business types encompassing scientific services, biopharmaceuticals, and application development in precision medicine, integrating solutions for scientific research, new drug development, and clinical testing. Throughout our collaboration with APTBIO, our team has deeply appreciated the forward-looking strategic vision and efficient execution capabilities of the senior management team led by Ms. Chen Wei. We believe that APTBIO will continue to maintain its leading position in China’s multi-omics industry and provide high-quality services to downstream customers.

Legend Capital, established in 2001, is a professional investment firm specializing in early-stage venture capital and growth-stage investments. Over the past two decades, Legend Capital has accumulated comprehensive and mature fund management expertise along with extensive industry resources. The firm’s mission is to foster corporate innovation and growth, thereby driving industrial progress and social development, through capital support and managerial assistance. For years, Legend Capital has been committed to providing proactive value-added services, contributing to the rise of multiple world-class leading enterprises and supporting the development of numerous national-level “Specialized, Refined, Differential, and Innovative” (SRDI) Little Giant companies. Meanwhile, Legend Capital actively fulfills its social responsibilities by establishing an ESG framework and pursuing sustainable development.

Haoyue Capital, established in January 2014, is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Haoyue Capital is committed to leveraging capital and research-driven insights to help outstanding Chinese healthcare companies successfully access the capital markets, thereby creating added value for its clients. The partnership team consists of senior investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Haoyue Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, Haoyue Capital completed more than 50 complex transactions involving private equity financing, M&A integration, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, maintaining a comprehensive leadership position across various healthcare sub-sectors.